


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) ~~A preventive or therapeutic agent for multiple sclerosis, which comprises the A method for treating or preventing multiple sclerosis, the method comprising administering to a patient in need thereof a therapeutically effective amount of a~~ compound represented by formula (I), or a pharmaceutically acceptable salt or hydrate thereof,



~~wherein, wherein,~~

T¹ represents a mono- or bicyclic 4- to 12-membered heterocyclic group comprising one or two nitrogen atoms in a ring, which may have substituents;

X represents a C₁₋₆ alkyl group that may have a substituent, a C₂₋₆ alkenyl group that may have a substituent, a C₂₋₆ alkynyl group that may have a substituent, a C₆₋₁₀ aryl group that may have a substituent, a 5- to 10-membered heteroaryl group that may have a substituent, a C₆₋₁₀ aryl C₁₋₆ alkyl group that may have a substituent, or a 5- to 10-membered heteroaryl C₁₋₆ alkyl group that may have a substituent;

in formula (I), the following formula



represents a single or double bond;
and when the formula



represents a single bond, Z^1 represents a group represented by the formula $-NR^2-$,
and Z^2 represents a carbonyl group;
when the formula



represents a double bond, Z^1 and Z^2 each independently represent a nitrogen atom
or a group represented by the formula $-CR^2=$;

R^1 and R^2 each independently represent a group represented by the formula $-A^0-A^1-A^2$
wherein, (wherein, A^0 represents a single bond or a C_{1-6} alkylene group that may
have one to three groups selected from a substituent group B described
below;

A^1 represents a single bond, an oxygen atom, a sulfur atom, a sulfinyl group, a
sulfonyl group, a carbonyl group, a formula $-O-CO-$, a formula $-CO-O-$, a
formula $-NR^A-$, a formula $-CO-NR^A-$, a formula $-NR^A-CO-$, a formula
 $-SO_2-NR^A-$, or a formula $-NR^A-SO_2-$;

A^2 and R^A each independently represent a hydrogen atom, a halogen atom, a
cyano group, a guanidino group, a C_{1-6} alkyl group, a C_{3-8} cycloalkyl
group, a C_{3-8} cycloalkenyl group, a C_{2-6} alkenyl group, a C_{2-6} alkynyl
group, a C_{6-10} aryl group, a 5- to 10-membered heteroaryl group, a 4- to
8-membered heterocyclic group, a 5- to 10-membered heteroaryl C_{1-6} alkyl
group, a C_{6-10} aryl C_{1-6} alkyl group, or a C_{2-7} alkyl carbonyl group;

with the proviso that A^2 and R^A may each independently have one to three groups
moieties selected from substituent group B, substituent group B consisting
of: ~~described below~~;

a hydroxyl group, a mercapto group, a cyano group, a nitro group, a halogen atom, a trifluoromethyl group, a trifluoromethoxy group, an alkylenedioxy group, a C₁₋₆ alkyl group that may have a substituent, a C₃₋₈ cycloalkyl group, a C₂₋₆ alkenyl group, a C₂₋₆ alkynyl group, a C₆₋₁₀ aryl group, a 5- to 10-membered heteroaryl group, a 4- to 8-membered heterocyclic group, a C₁₋₆ alkoxy group, a C₁₋₆ alkylthio group;
groups represented by the formulae -SO₂-NR^{B1}-R^{B2}, -NR^{B1}-CO-R^{B2}, and -NR^{B1}-R^{B2},
where R^{B1} and R^{B2} each independently represent a hydrogen atom or a C₁₋₆ alkyl group,
a group represented by the formula -CO-R^{B3},
where R^{B3} represents a 4- to 8-membered heterocyclic group,
and groups represented by the formulae -CO-R^{B4}-R^{B5} and -CH₂-CO-R^{B4}-R^{B5}
where R^{B4} represents a single bond, an oxygen atom, or a formula -NR^{B6}-; and
R^{B5} and R^{B6} each independently represent a hydrogen atom, a C₁₋₆ alkyl group, a C₃₋₈ cycloalkyl group, a C₂₋₆ alkenyl group, a C₂₋₆ alkynyl group, a C₆₋₁₀ aryl group, a 5- to 10-membered heteroaryl group, a 4- to 8-membered heterocyclic C₁₋₆ alkyl group, a C₆₋₁₀ aryl C₁₋₆ alkyl group, or a 5-10-membered heteroaryl C₁₋₆ alkyl group; and


when Z² represents the formula -CR²=, R¹ and R² may together form a 5- to 7-membered ring; ring.

<Substituent group B>

substituent group B refers to a group consisting of:


a hydroxyl group, a mercapto group, a cyano group, a nitro group, a halogen atom, a trifluoromethyl group, a trifluoromethoxy group, an alkenedioxy group, a C₁₋₆ alkyl group that may have a substituent, a C₃₋₈ cycloalkyl group, a C₂₋₆ alkenyl group, a C₂₋₆ alkynyl group, a C₆₋₁₀ aryl group, a 5- to 10-membered heteroaryl group, a 4- to 8-membered heterocyclic group, a C₁₋₆ alkoxy group, a C₁₋₆ alkylthio group, groups represented by the formulae -SO₂-NR^{B1}-R^{B2}, -NR^{B1}-CO-R^{B2}, and -NR^{B1}-R^{B2} (where R^{B1} and R^{B2} each independently represent a hydrogen atom or a C₁₋₆ alkyl group), a group represented by the formula -CO-R^{B3} (where R^{B3} represents a 4- to 8-membered heterocyclic group), and groups represented by the formulae -CO-R^{B4}-R^{B5} and -CH₂-CO-R^{B4}-R^{B5} (where R^{B4} represents a single bond, an oxygen atom, or a formula -NR^{B6}, R^{B5} and R^{B6} each independently represent a hydrogen atom, a C₁₋₆ alkyl group, a C₃₋₈ cycloalkyl group, a C₂₋₆ alkenyl group, a C₂₋₆ alkynyl group, a C₆₋₁₀ aryl group, a 5- to 10-membered heteroaryl group, a 4- to 8-membered heterocyclic C₁₋₆ alkyl group, a C₆₋₁₀ aryl C₁₋₆ alkyl group, or a 5-10-membered heteroaryl C₁₋₆ alkyl group)}.

2. (Currently Amended) The method of claim 1, wherein the compound has the formula: A preventive or therapeutic agent for multiple sclerosis, which comprises the compound represented by formula (II), or a salt or hydrate thereof;




[wherein, X, R¹, R² and T¹ have the same meaning as X, R¹, R² and T¹ of claim 1].

3. (Currently Amended) The method of claim 1, wherein the compound has the formula: A preventive or therapeutic agent for multiple sclerosis, which comprises the compound represented by formula (III), or a salt or hydrate thereof;



[wherein, X, R¹, R² and T¹ have the same meaning as X, R¹, R² and T¹ of claim 1].

4. (Currently Amended) The method of claim 1, wherein the compound has the formula: A preventive or therapeutic agent for multiple sclerosis, which comprises the compound represented by formula (IV), or a salt or hydrate thereof,



[wherein, X, R¹, R² and T¹ have the same meaning as X, R¹, R² and T¹ of claim 1].

5. (Currently Amended) The method of claim 1, A preventive or therapeutic agent for multiple sclerosis, which comprises the compound of any one of claims 1 to 4, or a salt or hydrate thereof, wherein T¹ is selected from the group consisting of:


an azetidin-1-yl group that may have a substituent;

a pyrrolidine-1-yl group that may have a substituent;

a piperidine-1-yl group that may have a substituent;

an azepan-1-yl group that may have a substituent; and

described above is a group represented by the following formula:



(where where n and m each independently represent zero or one, one), an azetidin-1-yl group that may have a substituent, a pyrrolidine-1-yl group that may have a substituent, a piperidine-1-yl group that may have a substituent, or an azepan-1-yl group that may have a substituent.

6. (Currently Amended) The method of claim 1, A preventive or therapeutic agent for multiple sclerosis, which comprises the compound of any one of claims 1 to 4, or a salt or hydrate thereof, wherein T¹ is selected from the group consisting of:


an azetidin-1-yl group that may have an amino group;

a pyrrolidin-1-yl group that may have an amino group,

a piperidin-1-yl group that may have an amino group;

an azepan-1-yl group that may have an amino group; and

described above is a group represented by the following formula:



(where where n and m each independently represent zero or one, one), an azetidin-1-yl group that may have an amino group, a pyrrolidin-1-yl group that may have an amino group, a piperidin-1-yl group that may have an amino group, or an azepan-1-yl group that may have an amino group.

7. (Currently Amended) The method of claim 1, A preventive or therapeutic agent for multiple sclerosis, which comprises the compound of any one of claims 1 to 4, or a salt

~~or hydrate thereof~~, wherein T¹ ~~described above~~ is a piperazine-1-yl group or a 3-aminopiperidine-1-yl group.

8. (Currently Amended) The method of claim 1, ~~A preventive or therapeutic agent for multiple sclerosis, which comprises the compound of any one of claims 1 to 4, or a salt or hydrate thereof~~, wherein T¹ ~~described above~~ is a piperazine-1-yl group.

9. (Currently Amended) The method of claim 1, ~~A preventive or therapeutic agent for multiple sclerosis, which comprises the compound according to any one of claims 1 to 8, or a salt or hydrate thereof~~, wherein X ~~described above~~ is a group represented by the formula -X¹-X² ~~(where where~~

X¹ represents a single bond or a methylene group that may have a substituent;

X² represents

a C₂₋₆ alkenyl group that may have a substituent,

a C₂₋₆ alkynyl group that may have a substituent, or

a phenyl group that may have a substituent. ~~substituent~~).

10. (Currently Amended) The method of claim 1, ~~A preventive or therapeutic agent for multiple sclerosis, which comprises the compound of any one of claims 1 to 8, or a salt or hydrate thereof~~, wherein X ~~described above~~ is a group represented by the formula -X¹¹-X¹² ~~(where where~~

X¹¹ represents a single bond or a methylene group;

X¹² represents

a C₂₋₆ alkenyl group,

a C₂₋₆ alkynyl group, or

a phenyl group that may have a substituent. ~~substituent~~).

11. (Currently Amended) ~~A preventive or therapeutic agent for multiple sclerosis, which comprises the compound~~. The method of claim 9 or 10, or a salt or hydrate thereof, wherein the phenyl group has ~~that may have~~ at position 2 a substituent selected from the

group consisting of: a hydroxyl group, a fluorine atom, a chlorine atom, a methyl group, an ethyl group, a fluoromethyl group, a vinyl group, a methoxy group, an ethoxy group, an acetyl group, a cyano group, a formyl group, and a C₂₋₇ alkoxycarbonyl group.

12. (Currently Amended) The method of claim 1, A preventive or therapeutic agent for multiple sclerosis, which comprises the compound of any one of claims 1 to 8, or a salt or hydrate thereof, wherein X is a 3-methyl-2-buten-1-yl group, a 2-butyne-1-yl group, a benzyl group, or a 2-chlorophenyl group.

13. (Currently Amended) The method of claim 1, A preventive or therapeutic agent for multiple sclerosis, which comprises the compound of any one of claims 1 to 8, or a salt or hydrate thereof, wherein X is a 2-butyne-1-yl group.

14. (Currently Amended) The method of claim 1, A preventive or therapeutic agent for multiple sclerosis, which comprises the compound of any one of claims 1 to 13, or a salt or hydrate thereof, wherein R¹ is a hydrogen atom or a group represented by the formula -A¹⁰-A¹¹-A¹² (wherein, wherein,

A¹⁰ represents a C₁₋₆ alkylene group that may have one to three moieties groups selected from substituent group C, substituent group C consisting of: described below;
a hydroxyl group, a nitro group, a cyano group, a halogen atom, a C₁₋₆ alkyl group, a C₁₋₆ alkoxy group, a C₁₋₆ alkylthio group, a trifluoromethyl group, a group represented by the formula -NR^{C1}-R^{C2},
where R^{C1} and R^{C2} each independently represent a hydrogen atom or a C₁₋₆ alkyl group,
and groups represented by the formulae -CO-R^{C3}-R^{C4} and -CH₂-CO-R^{C3}-R^{C4},
where R^{C3} represents a single bond, an oxygen atom, or a formula -NR^{C5}-;
and
R^{C4} and R^{C5} each independently represent a hydrogen atom or a C₁₋₆ alkyl group;

A¹¹ represents a single bond, an oxygen atom, a sulfur atom, or a carbonyl group;

A¹² represents

a hydrogen atom,

a C₆₋₁₀ aryl group that may have one to three moieties groups selected from
substituent group C-described below,

a 5- to 10-membered heteroaryl group that may have one to three moieties groups
selected from substituent group C described below,

a 5- to 10-membered heteroaryl C₁₋₆ alkyl group that may have one to three
moieties groups selected from substituent group C-described below, or

a C₆₋₁₀ aryl C₁₋₆ alkyl group that may have one to three moieties groups selected
from substituent group C-described below);

<Substituent group C>

substituent group C refers to a group consisting of:

a hydroxyl group, a nitro group, a cyano group, a halogen atom, a C₁₋₆ alkyl
group, a C₁₋₆ alkoxy group, a C₁₋₆ alkylthio group, a trifluoromethyl group, a
group represented by the formula -NR^{C1}-R^{C2} (where R^{C1} and R^{C2} each
independently represent a hydrogen atom or a C₁₋₆ alkyl group), and groups
represented by the formulae -CO-R^{C3}-R^{C4} and -CH₂-CO-R^{C3}-R^{C4} (where R^{C3}
represents a single bond, an oxygen atom, or a formula -NR^{C5}-; and R^{C4} and R^{C5}
each independently represent a hydrogen atom or a C₁₋₆ alkyl group).

15. (Currently Amended) The method of claim 1, A preventive or therapeutic
agent for multiple sclerosis, which comprises the compound of any one of claims 1 to 13, or a
salt or hydrate thereof, wherein

R¹ described above is

a hydrogen atom,

a C₁₋₆ alkyl group that may have one to three moieties groups selected from substituent
group C described below, substituent group C consisting of:

a hydroxyl group, a nitro group, a cyano group, a halogen atom, a C₁₋₆ alkyl group, a C₁₋₆ alkoxy group, a C₁₋₆ alkylthio group, a trifluoromethyl group, a group represented by the formula -NR^{C1}-R^{C2}, where R^{C1} and R^{C2} each independently represent a hydrogen atom or a C₁₋₆ alkyl group, and groups represented by the formulae -CO-R^{C3}-R^{C4} and -CH₂-CO-R^{C3}-R^{C4} where R^{C3} represents a single bond, an oxygen atom, or a formula -NR^{C5}-; and R^{C4} and R^{C5} each independently represent a hydrogen atom or a C₁₋₆ alkyl group;

a 5- to 10-membered heteroaryl C₁₋₆ alkyl group that may have one to three moieties groups selected from substituent group C described below, or

a C₆₋₁₀ aryl C₁₋₆ alkyl group that may have one to three moieties groups selected from substituent group C described below;

<Substituent group C>

substituent group C refers to a group consisting of:

a hydroxyl group, a nitro group, a cyano group, a halogen atom, a C₁₋₆ alkyl group, a C₁₋₆ alkoxy group, a C₁₋₆ alkylthio group, a trifluoromethyl group, a group represented by the formula -NR^{C1}-R^{C2} (where R^{C1} and R^{C2} each independently represent a hydrogen atom or a C₁₋₆ alkyl group), and groups represented by the formulae -CO-R^{C3}-R^{C4} and -CH₂-CO-R^{C3}-R^{C4} (where R^{C3} represents a single bond, an oxygen atom, or a formula -NR^{C5}-; and R^{C4} and R^{C5} each independently represent a hydrogen atom or a C₁₋₆ alkyl group).

16. (Currently Amended) The method of A preventive or therapeutic agent for multiple sclerosis, which comprises the compound of claim 14 or 15, or a salt or hydrate thereof, wherein substituent group C consists of a cyano group, a C₁₋₆ alkoxy group, a C₂₋₇ alkoxycarbonyl group, and halogen atom.

17. (Currently Amended) The method of claim 1, ~~A preventive or therapeutic agent for multiple sclerosis, which comprises the compound of any one of claims 1 to 13, or a salt or hydrate thereof,~~ wherein R^1 ~~described above~~ is a methyl group, a cyanobenzyl group, fluorocyanobenzyl group, a phenethyl group, a 2-methoxyethyl group, or a 4-methoxycarbonylpyridin-2-yl group.

18. (Currently Amended) The method of claim 1, ~~A preventive or therapeutic agent for multiple sclerosis, which comprises the compound of any one of claims 1 to 13, or a salt or hydrate thereof,~~ wherein R^1 is a methyl group or a 2-cyanobenzyl group.

19. (Currently Amended) The method of claim 1, ~~A preventive or therapeutic agent for multiple sclerosis, which comprises the compound of any one of claims 1 to 18, or a salt or hydrate thereof,~~ wherein
 R^2 is

a hydrogen atom,
a cyano group, or
a group represented by the formula $-A^{21}-A^{22}$

(where where A^{21} represents

a single bond,
an oxygen atom,
a sulfur atom,
a sulfinyl group,
a sulfonyl group,
a carbonyl group,
a formula $-O-CO-$,
a formula $-CO-O-$,
a formula $-NR^{A2}-$,
a formula $-CO-NR^{A2}-$,
or a formula $-NR^{A2}-CO-$;

A²² and R^{A2} each independently represent a hydrogen atom, a cyano group, a C₁₋₆ alkyl group, a C₃₋₈ cycloalkyl group, a C₂₋₆ alkenyl group, a C₂₋₆ alkynyl group, a C₆₋₁₀ aryl group, a 5- to 10-membered heteroaryl group, a 4- to 8-membered heterocyclic group, a 5- to 10-membered heteroaryl C₁₋₆ alkyl group, or a C₆₋₁₀ aryl C₁₋₆ alkyl group; with the proviso that A²² and R^{A2} each independently may have one to three moieties groups selected from substituent group D, substituent group D consisting of:

a hydroxyl group,

a cyano group,

a nitro group,

a halogen atom,

a C₁₋₆ alkyl group,

a C₁₋₆ alkoxy group,

a C₁₋₆ alkylthio group,

a trifluoromethyl group,

a group represented by the formula -NR^{D1}-R^{D2}

where R^{D1} and R^{D2} each independently

represent a hydrogen atom or a C₁₋₆

alkyl group,

a group represented by the formula -CO-R^{D3}

where R^{D3} represents a 4- to 8-membered

heterocyclic group, and

a group represented by the formula -CO-R^{D4}-R^{D5}

where R^{D4} represents a single bond, an

oxygen atom, or a formula -NR^{D6}-;

R^{D5} and R^{D6} each independently

represent a hydrogen atom, a

C₃₋₈ cycloalkyl group, or a
C₁₋₆ alkyl group.

D-described below);

<Substituent group D>

substituent group D refers to a group consisting of:

a hydroxyl group, a cyano group, a nitro group, a halogen atom, a C₁₋₆ alkyl group, a C₁₋₆ alkoxy group, a C₁₋₆ alkylthio group, a trifluoromethyl group, a group represented by the formula -NR^{D1}-R^{D2} (where R^{D1} and R^{D2} each independently represent a hydrogen atom or a C₁₋₆ alkyl group), a group represented by the formula -CO-R^{D3} (where R^{D3} represents a 4 to 8-membered heterocyclic group), and a group represented by the formula -CO-R^{D4}-R^{D5} (where R^{D4} represents a single bond, an oxygen atom, or a formula -NR^{D6}-; R^{D5} and R^{D6} each independently represent a hydrogen atom, a C₃₋₈ cycloalkyl group, or a C₁₋₆ alkyl group);

20. (Currently Amended) The method of claim 1, A preventive or therapeutic agent for multiple sclerosis, which comprises the compound of any one of claims 1 to 18, or a salt or hydrate thereof; wherein

R² described above is

a hydrogen atom,

a cyano group,

a carboxy group,

a C₂₋₇ alkoxy carbonyl group,

a C₁₋₆ alkyl group,

a group represented by the formula -CONR^{D7}R^{D8}

(wherein wherein R^{D7} and R^{D8} each independently represent a hydrogen atom or a C₁₋₆ alkyl group, group);

or a group represented by the formula -A²³-A²⁴

(where where A²³ represents

an oxygen atom,

- a sulfur atom, or
- a formula $-\text{NR}^{\text{A}3}-$;
- A^{24} and $\text{R}^{\text{A}3}$ each independently represent
 - a hydrogen atom,
 - a C_{1-6} alkyl group that may have a moiety group selected from substituent group D1 described below; D1, substituent group D1 consisting of:
 - a carboxy group,
 - a C_{2-7} alkoxycarbonyl group,
 - a C_{1-6} alkyl group,
 - a group represented by the formula $-\text{CONR}^{\text{D}7}\text{R}^{\text{D}8}$
 - wherein $\text{R}^{\text{D}7}$ and $\text{R}^{\text{D}8}$ each independently represent a
 - hydrogen atom or a C_{1-6} alkyl group,
 - a pyrrolidin-1-ylcarbonyl group,
 - a C_{1-6} alkyl group, and
 - a C_{1-6} alkoxy group,
 - a C_{3-8} cycloalkyl group that may have a moiety group selected from substituent group D1 described below,
 - a C_{2-6} alkenyl group that may have a moiety group selected from substituent group D1 described below,
 - a C_{2-6} alkynyl group that may have a moiety group selected from substituent group D1 described below,
 - a phenyl group that may have a moiety group selected from substituent group D1 described below, or
 - a 5- to 10-membered heteroaryl group that may have a moiety group selected from substituent group D1. D1 described below);

<Substituent group D1>

substituent group D1 refers to a group consisting of:

a carboxy group, a C₂₋₇ alkoxycarbonyl group, a C₁₋₆ alkyl group, a group represented by the formula -CONR^{D7}R^{D8} (wherein R^{D7} and R^{D8} each independently represent a hydrogen atom or a C₁₋₆ alkyl group), a pyrrolidin-1-ylcarbonyl group, a C₁₋₆ alkyl group, and a C₁₋₆ alkoxy group.

21. (Currently Amended) The method of claim 1, A preventive or therapeutic agent for multiple sclerosis, which comprises the compound of any one of claims 1 to 18, or a salt or hydrate thereof, wherein

R² described above is

- a hydrogen atom,
- a methyl group,
- a cyano group,
- a C₁₋₆ alkoxy group, or
- a group represented by the formula -A²⁵-A²⁶

(where ~~where~~ A²⁵ represents

- an oxygen atom,
- a sulfur atom, or
- a formula -NR^{A4};

A²⁶ and R^{A4} each independently represent

- a hydrogen atom,
- a C₁₋₆ alkyl group that may have a moiety group selected from substituent group ~~D1~~ described below D1, substituent group D1 consisting of:

a carboxy group,

a C₂₋₇ alkoxycarbonyl group,

a C₁₋₆ alkyl group,

a group represented by the formula -CONR^{D7}R^{D8}

wherein R^{D7} and R^{D8} each independently represent a

hydrogen atom or a C₁₋₆ alkyl group,

a pyrrolidin-1-ylcarbonyl group,

a C₁₋₆ alkyl group, and

a C₁₋₆ alkoxy group;

a C₃₋₈ cycloalkyl group that may have a moiety group selected from substituent group D1 described below, or

a phenyl group that may have a moiety group selected from substituent group D1. D1 described below);


<Substituent group D1>

substituent group D1 refers to a group consisting of:

a carboxy group, a C₂₋₇ alkoxy carbonyl group, a C₁₋₆ alkyl group, a group represented by the formula $\text{CONR}^{\text{D7}}\text{R}^{\text{D8}}$ (wherein R^{D7} and R^{D8} each independently represent a hydrogen atom or a C₁₋₆ alkyl group), a pyrrolidin-1-yl carbonyl group, a C₁₋₆ alkyl group, and a C₁₋₆ alkoxy group.

22. (Currently Amended) The method of claim 1, A preventive or therapeutic agent for multiple sclerosis, which comprises the compound of any one of claims 1 to 18, or a salt or hydrate thereof, wherein
R² described above is

a hydrogen atom,
a cyano group,
a methoxy group,
a carbamoylphenyloxy group, or
a group represented by the following formula:



(where where A²⁷ represents an oxygen atom, a sulfur atom, or -NH-; and

A²⁸ and A²⁹ each independently represent a hydrogen atom or a C₁₋₆ alkyl group.
~~group~~;

23. (Currently Amended) The method of claim 1, A preventive or therapeutic agent for multiple sclerosis, which comprises the compound of any one of claims 1 to 18, or a salt or hydrate thereof, wherein R² ~~described above~~ is a hydrogen atom, a cyano group, or a 2-carbamoylphenyloxy group.

24. (Currently Amended) The method ~~A preventive or therapeutic agent for multiple sclerosis, which comprises the compound of claim 1, or a salt or hydrate thereof,~~ wherein the compound represented by formula (I) is ~~any one of the compounds selected from the group consisting of:~~

7-(2-butynyl)-1,3-dimethyl-8-(piperazin-1-yl)-3,7-dihydropurine-2,6-dione,
7-(2-butynyl)-2-cyano-1-methyl-8-(piperazin-1-yl)-1,7-dihydropurin-6-one,
3-(2-butynyl)-5-methyl-2-(piperazin-1-yl)-3,5-dihydroimidazo[4,5-d]pyridazin-4-one,
2-(3-aminopiperidin-1-yl)-3-(2-butynyl)-5-methyl-3,5-dihydroimidazo[4,5-d]pyridazin-4-one,
2-[7-(2-butynyl)-1-methyl-6-oxo-8-(piperazin-1-yl)-6,7-dihydro-1H-purin-2-yloxy]benzamide,
7-(2-butynyl)-1-(2-cyanobenzyl)-6-oxo-8-(piperazin-1-yl)-6,7-dihydro-1H-purine-2-carbonitrile,
and
2-[3-(2-butynyl)-4-oxo-2-(piperazin-1-yl)-3,4-dihydroimidazo[4,5-d]pyridazin-5-ylmethyl]benzonitrile.

25. (Currently Amended) The method ~~A preventive or therapeutic agent for multiple sclerosis, which comprises the compound of claim 1, or a salt or hydrate thereof,~~ wherein the compound represented by formula (I) is ~~any one of the compounds selected from the group consisting of:~~

7-(2-butynyl)-2-cyano-1-methyl-8-(piperazin-1-yl)-1,7-dihydropurin-6-one,
3-(2-butynyl)-5-methyl-2-(piperazin-1-yl)-3,5-dihydroimidazo[4,5-d]pyridazin-4-one,
2-(3-aminopiperidin-1-yl)-3-(2-butynyl)-5-methyl-3,5-dihydroimidazo[4,5-d]pyridazin-4-one,
2-[7-(2-butynyl)-1-methyl-6-oxo-8-(piperazin-1-yl)-6,7-dihydro-1H-purin-2-yloxy]benzamide,

7-(2-butynyl)-1-(2-cyanobenzyl)-6-oxo-8-(piperazin-1-yl)-6,7-dihydro-1H-purine-2-carbonitrile,
and
2-[3-(2-butynyl)-4-oxo-2-(piperazin-1-yl)-3,4-dihydroimidazo[4,5-d]pyridazin-5-ylmethyl]benzonitrile.